Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

OMEGA THERAPEUTICS, INC.

(OMGA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Omega Therapeutics' : Q2 Loss Widens as Operating Expenses Rise

09/10/2021 | 07:40am EDT


© MT Newswires 2021
All news about OMEGA THERAPEUTICS, INC.
10/14OMEGA THERAPEUTICS : Working With Stanford University to Explore Use of Omega Epigenomic C..
MT
10/14OMEGA THERAPEUTICS : Announces Strategic Research Collaboration with Stanford University S..
PR
10/14Omega Therapeutics, Inc. Announces Strategic Research Collaboration with Stanford Unive..
CI
09/27OMEGA THERAPEUTICS : to Present at the Chardan Virtual 5th Annual Genetic Medicines Confer..
PR
09/20OMEGA THERAPEUTICS, INC.(NASDAQGS : OMGA) added to S&P TMI Index
CI
09/10OMEGA THERAPEUTICS' : Q2 Loss Widens as Operating Expenses Rise
MT
09/10OMEGA THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
09/10OMEGA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Statem..
AQ
09/10OMEGA THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Outlines Key Corpor..
PR
09/10Omega Therapeutics, Inc. Announces Unaudited Earnings Results for the Second Quarter an..
CI
More news
Analyst Recommendations on OMEGA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -82,4 M - -
Net cash 2021 206 M - -
P/E ratio 2021 -8,40x
Yield 2021 -
Capitalization 971 M 971 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees -
Free-Float 96,4%
Chart OMEGA THERAPEUTICS, INC.
Duration : Period :
Omega Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OMEGA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 20,34 $
Average target price 29,50 $
Spread / Average Target 45,0%
EPS Revisions
Managers and Directors
Mahesh Karande President, Chief Executive Officer & Director
Roger A. Sawhney Chief Financial Officer
Noubar B. Afeyan Chairman
Thomas McCauley Chief Scientific Officer
Mary T. Szela Director
Sector and Competitors
1st jan.Capi. (M$)
OMEGA THERAPEUTICS, INC.0.00%971
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414